Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07098364	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma	suspended	Phase 1 / Phase 2	33	Fred Hutchinson Cancer CenterOTHER	1	Sep 11, 2026	clinicaltrials
NCT07388563	Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma	suspended	Phase 1	20	National Cancer Institute (NCI)NIH	1	Aug 26, 2026	clinicaltrials